Ivermectin 3Mg Tab

DRUG3 trials

Sponsors

Washington University School of Medicine, Center for Research on Filariasis and Other Tropical Diseases, Cameroon, National University Hospital, Singapore

Conditions

Covid-19LoiasisOnchocerciasisOnchocerciasis, Ocular

Phase 2

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

CompletedNCT04049851

Center for Research on Filariasis and Other Tropical Diseases, CameroonLoiasis, Onchocerciasis, Ocular

Start: 2022-04-07End: 2023-07-22Updated: 2025-02-24

Phase 3

A Preventive Treatment for Migrant Workers at High-risk of COVID-19

CompletedNCT04446104

National University Hospital, SingaporeCovid-19

Start: 2020-05-13End: 2020-08-31Updated: 2020-10-19

Unknown Phase

Ocular Changes After Ivermectin - (DOLF IVM/Oncho)

CompletedNCT03517462

Washington University School of MedicineOnchocerciasis

Start: 2018-08-06End: 2019-08-23Updated: 2020-12-31

Related Papers

High CD4⁺ T-cell responses in seronegative individuals following SARS-CoV-2 exposure during a dormitory outbreak

International Journal of Infectious Diseases2025-08-21

Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin in <i>Loa loa</i>–Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial Densities

Open Forum Infectious Diseases2024-04-254 citations

Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection

PLoS neglected tropical diseases2022-04-27145 citations